ClinicalTrials.gg

Program

obefazimod

Also written as “ABX464”, “ABX464 50mg” and “Obefazimod 50 mg Capsule”.

Its studies are mostly in Colitis, Ulcerative · Crohn Disease · Arthritis, Rheumatoid · HIV Infections · COVID-19, led by Abivax.

Furthest: phase 3, since Apr 3, 201921 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abivax214 open or runningphase 3since Apr 3, 2019Apr 10, 2015Dec 2026phase 2 · NCT06456593

Also a collaborator on its studies: quotient-sciences and Orion Corporation, Orion Pharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 10, 2015.

  1. Nov 29, 2018Phase 2 study in Colitis, UlcerativeNCT03760003 · 355 enrolled · United States, Austria, Belarus and more
  2. Jan 15, 2019Phase 2 study in Arthritis, RheumatoidNCT03813199 · 60 enrolled · Belgium, Czechia, France and more
  3. Apr 3, 2019Phase 3 study in Crohn DiseaseNCT03905109 · Belgium
  4. Jul 5, 2019Phase 2 study in Colitis, UlcerativeNCT04023396 · 217 enrolled · Austria, Belarus, Belgium and more
  5. Aug 6, 2019Phase 2 study in Arthritis, RheumatoidNCT04049448 · 40 enrolled · Belgium, France, Hungary and more
  6. May 18, 2020Phase 3 study in COVID-19NCT04393038 · 509 enrolled · Belgium, Brazil, France and more
  7. Aug 30, 2021Phase 1 study in Healthy VolunteersNCT05032560 · 48 enrolled · Japan
  8. Oct 11, 2021Phase 1 study in HealthyNCT05121714 · 59 enrolled · United Kingdom
  9. Dec 15, 2021Phase 2 study in Colitis, UlcerativeNCT05177835 · 203 enrolled · Austria, Belgium, Canada and more
  10. Aug 17, 20222 phase 3 studies in Colitis, UlcerativeNCT05507216, NCT05507203
  11. Sep 7, 2022Phase 3 study in Colitis, UlcerativeNCT05535946 · 1,116 enrolled · United States, Argentina, Australia and more
  12. May 16, 2024Phase 2 study in Crohn DiseaseNCT06456593 · 212 planned · United States, Belgium, Czechia and more
  13. Feb 25, 2026Phase 1 study in HealthyNCT07453784 · 44 planned · United Kingdom
  14. Nov 13, 2026Primary completion moved from 2026-09 to 2027-04Date moved laterphase 1 · +7 months · NCT07453784

Ahead

  1. Dec 2026Primary completion: phase 2 study in Crohn DiseaseNCT06456593
  2. Apr 2027Primary completion: phase 1 study in HealthyNCT07453784
  3. Mar 2028Primary completion: phase 2 study in Colitis, UlcerativeNCT05177835

TargetBeta

NCBP1 →NCBP2 →read by rule
“Cap binding complex modulator”ChEMBL 37, by rule

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07453784Healthy · United Kingdom1RecruitingApr 202744
NCT06456593Crohn Disease · United States, Belgium, Czechia and more2RecruitingDec 2026212
NCT05535946Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingApr 28, 20261,116
NCT05507216Colitis, Ulcerative · United States, Argentina, Belgium and more3CompletedJun 24, 2025636
NCT05507203Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedJun 24, 2025639
NCT05177835Colitis, Ulcerative · Austria, Belgium, Canada and more2Active, not recruitingMar 2028203
NCT05121714Healthy · United Kingdom1CompletedMay 18, 202159
NCT05032560Healthy Volunteers · Japan1CompletedFeb 18, 202248
NCT04393038COVID-19 · Belgium, Brazil, France and more3TerminatedMar 5, 2021509
NCT04049448Arthritis, Rheumatoid · Belgium, France, Hungary and more2CompletedJan 23, 202340
NCT04023396Colitis, Ulcerative · Austria, Belarus, Belgium and more2CompletedFeb 23, 2023217
NCT03905109Crohn Disease · Belgium3WithdrawnSep 19, 20220
NCT03813199Arthritis, Rheumatoid · Belgium, Czechia, France and more2CompletedApr 27, 202160
NCT03760003Colitis, Ulcerative · United States, Austria, Belarus and more2CompletedApr 1, 2021355
NCT03368118Colitis, Ulcerative · Belgium2CompletedJul 12, 202222
NCT03093259Colitis, Ulcerative · Austria, Belgium, Czechia and more2CompletedJul 25, 201832
NCT02990325HIV Infections · Spain2CompletedDec 27, 201836
NCT02792686Healthy Volunteers · France1CompletedJul 201424
NCT02735863HIV Infections · Belgium, France, Spain2CompletedAug 30, 201730
NCT02731885Healthy Volunteers · Mauritius1CompletedJun 201548
NCT02452242Human Immunodeficiency Virus Infections · Mauritius, Thailand2CompletedDec 201570

How it is read

Names in the registry

  • “ABX464”, 15 entries
  • “ABX464 50mg”, 3 entries
  • “Obefazimod 50 mg Capsule”, 1 entry
  • “Obefazimod”, 1 entry
  • “ABX464 100 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.